Coagulation Tests: PT, aPTT, TT, RT, dRVVT, Mixing Study
ðđ āļāļāļāļģ (Introduction)
āļāļēāļĢāļāļĢāļ§āļāļĢāļ°āļāļāļāļēāļĢāđāļ็āļāļัāļ§āļāļāļāđāļĨืāļāļāļี่āđāļ้āļ่āļāļĒāđāļāđāļ§āļāļāļิāļัāļิ
āđāļ้āđāļ่
- Prothrombin
Time (PT) āđāļĨāļ° INR → āļāļĢāļ°āđāļĄิāļ extrinsic āđāļĨāļ° common pathway
- Activated
Partial Thromboplastin Time (aPTT) →
āļāļĢāļ°āđāļĄิāļ intrinsic āđāļĨāļ° common
pathway
- Thrombin
Time (TT) → āļāļĢāļ°āđāļĄิāļ āļั้āļāļāļāļāļŠุāļāļ้āļēāļĒāļāļāļāļāļēāļĢāļŠāļĢ้āļēāļ fibrin
- Reptilase
Time (RT) → āđāļ้āđāļĒāļāļāļĢāļี prolong TT āļāļēāļ heparin
- dRVVT
(Dilute Russell Viper Venom Time) →
āļāļĢāļ§āļāļŦāļē lupus anticoagulant (LA)
- Mixing
study → āđāļ้āđāļĒāļāļŠāļēāđāļŦāļุ factor deficiency vs inhibitor
ðđ āļāļēāļĢāđāļ็āļāđāļĨāļ°āļัāļāļāļēāļĢāļัāļ§āļāļĒ่āļēāļ
āļāļĢāļ°āđāļ็āļ |
āļĢāļēāļĒāļĨāļ°āđāļีāļĒāļāļŠāļģāļัāļ |
āļāļิāļāļŦāļĨāļāļ |
āđāļ้āļŦāļĨāļāļ sodium
citrate 3.2% (blue top) āļัāļāļĢāļēāļŠ่āļ§āļ āđāļĨืāļāļ 9
: citrate 1 |
āļāļĢิāļĄāļēāļāđāļĨืāļāļ |
āļ้āļāļāđāļิāļĄāđāļ็āļĄ ≥90%
āļāļāļāļāļĢิāļĄāļēāļāļĢāļี่āļāļģāļŦāļāļ āļŦāļēāļāļ้āļāļĒāđāļิāļāđāļ → āļ่āļē PT/aPTT
āļĒāļēāļ§āļิāļāļāļĢิāļ |
āļāļēāļĢāļāļŠāļĄ |
āļāļ§่āļģāļŦāļĨāļāļāđāļāļē āđ
āļัāļāļีāļŦāļĨัāļāđāļāļēāļ°āđāļĨืāļāļ āļŦ้āļēāļĄāđāļāļĒ่āļē |
āđāļ§āļĨāļēāđāļĨāļ°āļุāļāļŦāļ ูāļĄิ |
āļāļĢāļ§āļāļ āļēāļĒāđāļ 24
āļāļĄ. āļŦāļēāļāļĨ่āļēāļ้āļē → factor V, VIII, protein S āļŠāļĨāļēāļĒ |
Polycythemia (Hct >55%) |
āļ้āļāļāļĨāļāļāļĢิāļĄāļēāļ citrate
āļĄิāļāļ°āļั้āļāļ่āļēāļāļ° āļĒāļēāļ§āļāļĨāļāļĄ (false prolongation) |
āļัāļ§āļāļĒ่āļēāļāļāļēāļāļŠāļēāļĒ IV/central
line |
āļ้āļāļ discard
āđāļĨืāļāļ 3–5 mL āđāļĢāļ āļ้āļāļāļัāļāļāļēāļĢāļāļ
heparin/citrate |
ðđ āļāļēāļĢāļāļāļŠāļāļāļŦāļĨัāļ
(Major Coagulation Tests)
1. Prothrombin Time (PT) / INR
- āļ§ัāļāđāļ§āļĨāļēāđāļāļāļēāļĢāđāļิāļ clot āļŦāļĨัāļāđāļŠ่ tissue
factor + Ca²⁺
- āļāļĢāļ°āđāļĄิāļ extrinsic (Factor VII) āđāļĨāļ° common
pathway (X, V, II, I)
- āļ่āļē PT āļāļāļิ ≈ 11–13 sec
- āļ่āļē INR = (Patient PT / Control PT)^ISI → āđāļ้ monitor
warfarin
- āļŠāļēāđāļŦāļุ PT āļĒāļēāļ§āļิāļāļāļāļิ
- Warfarin
/ Vitamin K deficiency
- Liver
disease
- DIC
- Factor
II, V, VII, X deficiency
- Antiphospholipid
antibody (anti-prothrombin type)
- Overcitrate
/ polycythemia (artifact)
2. Activated Partial Thromboplastin Time (aPTT)
- āļ§ัāļāđāļ§āļĨāļēāđāļāļāļēāļĢ clot āļŦāļĨัāļāđāļŠ่ phospholipid
+ silica/kaolin + Ca²⁺
- āļāļĢāļ°āđāļĄิāļ intrinsic (XII, XI, IX, VIII) āđāļĨāļ°
common pathway
- āļāļāļิ ≈ 25–35
sec (āļึ้āļāļัāļ reagent)
- āđāļĄ่āļĄีāļĄāļēāļāļĢāļāļēāļāđāļีāļĒāļāļ้āļēāļĄāļŦ้āļāļāđāļĨ็āļāđāļŦāļĄืāļāļ INR
- āđāļ้ monitor UFH, direct thrombin inhibitor
- āļŠāļēāđāļŦāļุ aPTT āļĒāļēāļ§āļิāļāļāļāļิ
- Heparin
/ DOAC / fondaparinux
- DIC
- Severe
liver disease
- VWD
(↓FVIII), Hemophilia
A/B, FXI deficiency
- Lupus
anticoagulant
- Factor
VIII inhibitor
- Artifactual
(heparin contamination, polycythemia)
Note: Deficiency āļāļāļ FXII,
prekallikrein, HMW kininogen →
aPTT āļĒāļēāļ§āđāļ่ āđāļĄ่āļāļģāđāļŦ้āđāļĨืāļāļāļāļāļ
3. Thrombin Time (TT)
- āļ§ัāļāļāļēāļĢāđāļāļĨี่āļĒāļ fibrinogen → fibrin āļŦāļĨัāļāđāļิāļĄ thrombin
- āļāļāļิ ≈ 14–19
sec
- TT āļĒāļēāļ§ āđāļĄื่āļ
- Hypo/dysfibrinogenemia
- Heparin
āļŦāļĢืāļ direct thrombin inhibitor
- DIC,
liver disease, paraproteinemia, hypoalbuminemia
- āđāļĄ่āđāļ้āđāļ็āļ screening test āđāļ่āđāļ้āļ่āļ§āļĒāđāļāļĨāļāļĨ prolonged
PT/aPTT
4. Reptilase Time (RT)
- āđāļ้āđāļāļāđāļāļĄ์āļāļēāļāļู Bothrops →
āđāļāļĨี่āļĒāļ fibrinogen →
fibrin
- āđāļĄ่āļูāļāļĒัāļāļĒั้āļāđāļāļĒ heparin/AT complex
- āđāļ้āđāļĒāļāļŠāļēāđāļŦāļุ TT āļĒāļēāļ§āļāļēāļ heparin:
- TT ↑, RT āļāļāļิ → heparin
effect
- TT ↑, RT ↑ → fibrinogen abnormality
5. Lupus Anticoagulant Tests / dRVVT
- āđāļ้āļāļĢāļ§āļāļŦāļē antiphospholipid antibody (LA) āļี่āļĒัāļāļĒั้āļāļāļēāļĢāđāļ็āļāļัāļ§ in vitro
- dRVVT āđāļ้āļิāļĐāļู Russell āđāļื่āļāļāļĢāļ°āļุ้āļ Factor X
→ āļ§ัāļāđāļ§āļĨāļēāđāļิāļ
clot
- LA
positive āđāļĄื่āļ
- aPTT
āļĒāļēāļ§
- āđāļĄ่āđāļ้āļŦāļĨัāļāđāļิāļĄ plasma āļāļāļิ (mixing
test)
- āđāļ่āđāļ้āđāļĄื่āļāđāļิāļĄ phospholipid āđāļิ่āļĄ
- āļŠāļēāđāļŦāļุāđāļีāļĒāļĄ: heparin, DOAC, high CRP
āđāļāļāļēāļāļāļĨิāļิāļ LA āļĄัāļāļŠัāļĄāļัāļāļ์āļัāļ
thrombosis āļĄāļēāļāļāļ§่āļē bleeding
6. Fibrinogen / D-dimer
āļāļēāļĢāļāļĢāļ§āļ |
āļāļ§āļēāļĄāļŦāļĄāļēāļĒ /
āļāļēāļĢāđāļ้ |
Fibrinogen level |
āļĨāļāđāļ DIC,
liver failure, fibrinolysis; āļāļāļิ 200–400 mg/dL |
D-dimer |
āļāļĨิāļāļ ัāļāļ์āļŠāļĨāļēāļĒ fibrin
crosslink → ↑ āđāļ DVT/PE,
DIC, trauma, infection, COVID-19; āļāļāļิ <500 ng/mL
(FEU) |
ðđ āļāļēāļĢāļāļĢāļ§āļāļิāđāļĻāļĐ
(Specific Factor Assay)
āđāļ้āđāļĄื่āļāļ้āļāļāļāļēāļĢāļĢāļ°āļุāļ§่āļē factor āđāļāļāļēāļ āđāļ่āļ
- PT
prolonged → āļāļĢāļ§āļ Factor VII
- aPTT
prolonged → āļāļĢāļ§āļ VIII, IX, XI, XII
- āļั้āļāļู่ prolonged →
āļāļĢāļ§āļ II, V, X, fibrinogen
- āđāļ้āļ§ิāļี clot-based assay āļŦāļĢืāļ chromogenic
assay
Chromogenic assay āļĄีāļāļĢāļ°āđāļĒāļāļ์āđāļ:
- Warfarin
interference (āđāļ้ FX chromogenic assay āđāļāļ
INR)
- Emicizumab
(āļ้āļāļāđāļ้ chromogenic FVIII assay āļี่āđāļ้
bovine reagent)
- DOAC
interference (āđāļ้ anti-Xa calibrated assay)
ðđ āļāļēāļĢāđāļāļĨāļāļĨāđāļื้āļāļāļ้āļāļāļāļ
PT/aPTT
āļāļĨāļāļĢāļ§āļ |
āļีāļāļ§āļēāļĄāļŦāļĨัāļ |
āļัāļ§āļāļĒ่āļēāļāļŠāļēāđāļŦāļุ |
PT↑, aPTT āļāļāļิ |
Extrinsic defect (Factor VII) |
Warfarin, Vit K deficiency, mild
liver disease |
PT āļāļāļิ,
aPTT↑ |
Intrinsic defect |
Heparin, VWD, Hemophilia, LA |
PT↑, aPTT↑ |
Common pathway defect |
DIC, severe liver disease, Vit K
deficiency, Warfarin overdose, Hypofibrinogenemia |
PT, aPTT āļāļāļิ
āđāļ่āļĄีāđāļĨืāļāļāļāļāļ |
Platelet/VWF/factor XIII defect |
Thrombocytopenia, mild VWD, FXIII
deficiency |
PT, aPTT āļŠั้āļāļิāļāļāļāļิ |
Hypercoagulable state āļŦāļĢืāļ sample error |
Malignancy, inflammation, TMA (thrombotic
microangiopathy), exercise |
ðđ āļāļēāļĢāđāļ้
Mixing Study
āļŦāļĨัāļāļāļēāļĢ:
- āļāļŠāļĄ plasma āļู้āļ่āļ§āļĒ 1:1 āļัāļ
plasma āļāļāļิ → āļāļāļŠāļāļ PT/aPTT āđāļŦāļĄ่
āļāļĨāļāļēāļĢāļāļāļŠāļāļ |
āļāļēāļĢāļีāļāļ§āļēāļĄ |
āļัāļ§āļāļĒ่āļēāļāļŠāļēāđāļŦāļุ |
āļ่āļēāđāļ้āļāļĨัāļāļāļāļิ (Corrects) |
Factor deficiency |
VWD, Hemophilia, Vit K
deficiency, liver disease |
āļ่āļēāđāļĄ่āđāļ้ (No
correction) |
Inhibitor presence |
Lupus anticoagulant, Heparin,
DOAC, Factor VIII inhibitor |
āđāļ้āļั่āļ§āļāļĢāļēāļ§āđāļ่āļāļĨัāļāļĒāļēāļ§āļŦāļĨัāļ
incubate |
Time-dependent inhibitor
(autoantibody) |
Acquired Factor VIII inhibitor |
āđāļāļāļĢāļี prolong PT/aPTT āļี่āđāļĄ่āļāļĢāļēāļāļŠāļēāđāļŦāļุ
āđāļāļ°āļāļģāđāļĢิ่āļĄāļāļēāļ retest + mixing study
ðđ āļāļēāļĢāļิāļāļāļēāļĄāļāļēāļĢāđāļŦ้āļĒāļē
Anticoagulant
āļĒāļē |
āļāļēāļĢāļāļĢāļ§āļāļŦāļĨัāļ |
āļāļĨāļ่āļ coagulation
test |
Warfarin (VKA) |
PT/INR (āđāļ้āļēāļŦāļĄāļēāļĒ 2–3) |
↑
PT/INR, āļāļēāļāļāļĢั้āļ ↑aPTT |
UFH (IV) |
aPTT āļŦāļĢืāļ anti-Xa |
↑
aPTT |
LMWH (SC) |
Anti-Xa (āļ้āļēāļ้āļāļ) |
↑
anti-Xa; aPTT āļĄัāļāđāļĄ่āđāļāļĨี่āļĒāļ |
Fondaparinux |
Anti-Xa (fondaparinux calibrated) |
↑
anti-Xa, āļāļēāļ ↑aPTT
āđāļĨ็āļāļ้āļāļĒ |
Direct Thrombin Inhibitor
(Dabigatran, Argatroban) |
aPTT, TT, Ecarin Clotting Time |
↑
aPTT, TT |
Direct Factor Xa Inhibitor
(Rivaroxaban, Apixaban) |
Anti-Xa (drug-specific) |
↑
PT, aPTT, ↑ anti-Xa |
ðđ āļŠāļĢุāļāļ āļēāļāļĢāļ§āļĄ
(Clinical Pearls)
- PT
/ INR → āđāļ้ monitor warfarin, āļāļĢāļ§āļ extrinsic
pathway
- aPTT
→ āđāļ้ monitor
UFH, āļāļĢāļ§āļ intrinsic pathway
- TT
/ RT → āđāļ้āļāļĢāļ§āļ heparin āļŦāļĢืāļ fibrinogen defect
- Mixing
study → āđāļ้āđāļĒāļ factor deficiency vs inhibitor
- LA
/ dRVVT → āļāļĢāļ§āļāļŦāļēāļ āļēāļ§āļ° antiphospholipid antibody
- D-dimer
→ āđāļ้ rule
out DVT/PE āđāļĨāļ°āļāļĢāļ°āđāļĄิāļ DIC
- Liver
disease / DIC → PT
āđāļĨāļ° aPTT āļĒāļēāļ§āļั้āļāļู่ āđāļ่ hemostasis
āļāļēāļāļĒัāļāļŠāļĄāļุāļĨ (rebalanced)
- Polycythemia
/ underfilled tube →
āļāļģāđāļŦ้āļ่āļē āļĒāļēāļ§āđāļีāļĒāļĄ āđāļ้
āļŠāļĢุāļāļŠั้āļāļŠāļģāļŦāļĢัāļāđāļāļāļĒ์: āļāļēāļĢāđāļāļĨāļāļĨ coagulation test āļ้āļāļāļู pattern
āļāļāļ PT/aPTT, āļāļĢāļ°āļ§ัāļิāļĒāļē, āđāļĨāļ° āļŠāļ āļēāļ§āļ°āļāļēāļāļāļĨิāļิāļ āļĢ่āļ§āļĄāļัāļ āļŦāļēāļāļāļāļ่āļēāļิāļāļāļāļิāđāļāļ isolated → āļāļģ mixing study āļāļēāļĢāļีāļāļ§āļēāļĄāļี่āļูāļāļ้āļāļāļ่āļ§āļĒāđāļĒāļāđāļ้āļĢāļ°āļŦāļ§่āļēāļ āđāļĢāļāđāļĨืāļāļāļāļāļ
(bleeding
tendency) āļัāļ āđāļĢāļāđāļĨืāļāļāđāļ็āļāļัāļ§āđāļิāļ (thrombophilia) āđāļ้āļāļĒ่āļēāļāđāļĄ่āļāļĒāļģ. |
āđāļĄ่āļĄีāļāļ§āļēāļĄāļิāļāđāļŦ็āļ:
āđāļŠāļāļāļāļ§āļēāļĄāļิāļāđāļŦ็āļ